Corbus Pharmaceuticals

Corbus helps people fight serious diseases like cancer and obesity. It makes new medicines that target specific paths in the body. The company works with research partners to test these treatments.

Medicines in the Making

• CRB-701: Antibody drug conjugate, which links a targeting protein to a cell-killing medicine; delivers treatment directly to specific cancer cells that express the Nectin-4 protein.
• CRB-913: Oral weight-loss drug that blocks the cannabinoid receptor type-1, a protein involved in metabolism; targets areas outside the brain to avoid psychiatric side effects.
• CRB-601: Monoclonal antibody, a lab-made protein that binds to specific targets in the body; designed to block signals that help tumors grow.
• Lenabasum: Oral medication that activates specific receptors to manage inflammation; currently undergoing trials for patients with systemic lupus erythematosus, an autoimmune disease.

Strategic Deals and Growth

• Licensed CRB-701 from CSPC Megalith Biopharmaceutical Co., Ltd. in February 2023 for development in North America and Europe.
• Partnered with Jenrin Discovery, LLC in 2018 to access a library of 600 compounds for metabolic disease research.
• Completed a public stock offering in November 2025 that raised $70.2 million in net proceeds for clinical trials.
• Secured antibody patents through a license agreement with The Regents of the University of California to expand its cancer treatment portfolio.

Science for Serious Illness

The company focuses on biological pathways that are already well-understood to increase the chances of clinical success. Its obesity program targets receptors in the body's periphery to improve safety compared to treatments that affect the brain.

Funding the Clinical Path

• Operating loss was $24.3 million in Q1 2026, worsening 22.9% from the previous year.
• Net loss reached $23 million in Q1 2026, worsening 35.3% year-over-year.
• Research and development spending hit $19.8 million in Q1 2026, up 27% as clinical testing expanded.
• Free cash flow was negative $25.6 million in Q1 2026, worsening 55.8% from the same period in 2025.

Bottom Line

Corbus has evolved into a clinical-stage specialist focusing on the high-growth oncology and metabolic disease markets. The company uses strategic licensing and equity funding to advance its drug pipeline through expensive regulatory phases.